The recent approval of ViiV Healthcare's once-daily, single-tablet anti-HIV regimen Triumeq by the US FDA and the European Commission (EC) will mean that the market monopoly currently held by ...

ViiV Healthcare, a pharmaceutical company developing HIV therapies, and other plaintiffs sued Hetero USA on May 3 in Delaware District Court over patent infringement claims. The court action ...

Months before that, ViiV Healthcare rolled out Backseat Hotseat, a campaign to normalize conversations about HIV prevention, with the help of comedians Phoebe Robinson and Matteo Lane. Over the course ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for two new formulations of ViiV Healthcare’s cabotegravir, offering a new prevention option for sexually ...

Pharma’s pandemic-era halo is slipping. After tracking a surge in the industry’s reputation, PatientView found patient groups ...

2 This expanded indication marks the first time an oral, two-drug, single-tablet regimen is available for adolescents between 12- and 18-years old living with HIV and underscores ViiV Healthcare ...

showed off a variety of Viiv models ranging from small footprint PCs the size of a wireless router to devices that looked more like stereo components to traditional tower PCs. The Viiv platform ...

It’s been 50 years of PrideFest in Denver and the two-day celebratory event’s entertainment lineup was just announced — and it includes some of the drag world’s ...

SAN ANTONIO — HIV is no longer a death sentence for those who live with it, and new therapies with benefits lasting longer ...

Data taken from [10,33–38]. Blake Max's spouse is employed as a regional medical scientist for ViiV Healthcare, which manufactures dolutegravir. The authors have no other relevant affiliations ...

The government of Colombia, after signaling its intent to do so at the end of 2023, issued a compulsory license on April 24 for access to generic versions of HIV drug dolutegravir, without the ...

May 7, 2024 Halozyme Therapeutics, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third ...